Australia's Amplia rises to 4-month high on Eli Lilly cancer drug trial collaboration
BUZZ-Australia's Amplia rises to 4-month high on Eli Lilly cancer drug trial collaboration ** Shares of Australia's Amplia Therapeutics ATX.AX rise as much as 37% to A$0.185, hitting their highest level since April 7
** Stock posts its biggest intraday pct gain since March 23
** The pharmaceutical firm signs a clinical trial collaboration and supply agreement with Eli Lilly LLY.N
** Says the deal to test company's experimental cancer drug narmafotinib in combination with Lilly's investigational KRAS inhibitor olomorasib in a clinical trial
** ATX up over 13% this year, including the day's move
(Reporting by Rajasik Mukherjee in Bengaluru)
Recent news on Amplia Therapeutics
See all newsBrief: Amplia Therapeutics Signs Collaboration And Supply Agreement With Lilly
Australia's Amplia rises to 4-month high on Eli Lilly cancer drug trial collaboration
Brief: Amplia Therapeutics Says Warwick Tong Will Retire As Board Chairman
Brief: Amplia Therapeutics Reports Four Additional Complete Responses And Improved Overall Survival Data In Accent Pancreatic Cancer Trial
Brief: Amplia Therapeutics Requests Trading Halt Pending Clinical Trial Results Announcement